The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have released guidance outlining how to identify confidential information and protect personal data within marketing authorisation applications, PharmaTimes reports. The document, open for public consultation until 1 September, explains what information requested in a marketing application can be released. The EMA and HMA say they are interested in the opinions of stakeholders, including healthcare professionals and patient groups, on the criteria for releasing and protecting personal data.
Full Story